Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.
You may also be interested in...
Sanofi’s Q4 update will highlight planned strategic changes and Dupixent’s key growth role, amid a strong rebound in quarterly US flu vaccine sales.
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.